You are not logged in.
When you hear on the news that no child has committed suicide while taking strattera only attempted it realize that is wrong my son was on strattera for 7 months when he did commit suicide. This drug needs to be taken off the market.
Offline
[quote]When you hear on the news that no child has committed suicide while taking strattera only attempted it realize that is wrong my son was on strattera for 7 months when he did commit suicide. This drug nebe taken off the market.[/quote] :cry: [quote]i am very sorry to hear about your son.my son was put on strattera 6 months ago.he became extremely violent towards us,tried to jump from an upstairs window saying he wanted to kill himself.and that people were watching and stealing from him.he has injured my husband.the health people did not seem to listen to us until now, it has been a nightmare.his strattera has been stopped NOW but it will be in his system for about 4 weeks.they kept telling us to stick with it,it would be better for him in the end.(we are in the uk).[/quote]
Offline
Our condolence goes out to you concerning your child that has been on Strattera for 7 months and he committed suicide. This drug company should be sued because they actually killed your son with Strattera and the side effects. Also the doctor who prescribed the drug for your son should not be practicing any longer. What is happening in America when doctors get away with murder and they cover up their serious mistake that caused a person to die and shorten their life.
Our son died at age 28 years old because of a doctor's serious mistake and another doctor called me at our computer store and admitted that the doctor treating our son killed him. But if this case came to court he would have to deny that he ever spoke with me. He could only help me to run this doctor out of town and this did not happen so the doctor that murdered our son is still practicing and we wonder how many other patients has he killed. Only God knows and one day it will be pay day for this doctor as we all have to answer for any evil we commit. We pray for this doctor as he needs help as I wonder how he can sleep at night without having horrible nightmares.
Our grandson who is our son that died at age 28 is his son is now on Strattera and we are concern about going to his funeral as we had to go to his Dad's funeral five years ago. Things are not right in America and things seem to be getting worse and worse.
We would like for our daughter-in-love to understand how dangerous it is for her to give Austin Strattera as we do not know all the horrible side effects. If you would be willing to help us get this message out to Jennifer before something serious happens to our grandson, we would certainly appreciate your help in this situation. Thank you for being bold and letting others know how Strattera is killing our young innocent children. May God help us!
Offline
I hope this will help, I don't have much time to post right now, but its a request by an investigative reporter in Sweden to the drug regulatory board in the UK (the MHRA):
"Request for an urgent safety review of Strattera
A long-term clinical trial of Strattera on adults, conducted by Eli Lilly and Professor Christopher Gillberg in Sweden has given a catastrophic result.
The application for the trial was turned in to the Research Ethics Committee at the University of Gothenburg, January 2003. According to the application the trial should test the effect of Strattera on 40 adults for 18 months, to see if a “possible positive effect remains”, and to study “[n]egative side effects short and long term…” (p. 3) [1]
On the question (p. 3) “which risks for harm and discomfort different participants can be subjected to” the answer was: “We estimate that the study does not involve any medical risks for the patient.” And: “Serious side effects are extremely rare.” (p. 4)
But the latest information about the trial says that 24 participants were recruited (of the 40 planned for). 4 persons of the 24 did not start. 20 remained. [2] (The trial is not ended and of course not published in any medical journal.)
The main result: 40 percent (n=8) of the participants had to end the study in advance due to fact that the harmful effects of Strattera were too serious.
The next most important result: 30 percent (n=6) of the participants had to end the study in advance due to fact that Strattera was ineffective.
15 percent (n=3) never came to the next visit or ended on own initiative. (This group should of course be counted to the category above, whereby the part ending due to no effect rises to 45 percent (n=9). (One person ended in advance due to other reasons.)
And: “One patient has completed the study. One patient remains in the study…”
The 40 percent (n=8) taken out of the study due to harmful effects were hit by liver disorder (“increased levels of transamines”, n=1), thyroid disorder (“increased thyroid levels”, n=1), aggressiveness/hostility (n=2), depression (n=3), increased blood pressure (n=1). [2; 3; 4]
In summary Christopher Gillberg and Eli Lilly have shown that the hypothesis did not hold: Strattera’s possible positive effect did not remain; the negative side effects were so serious that 40 percent of the participants had to end the treatment in advance (the medical risks for the patients were too big).
18 of 20 (90 percent) fell out of the study before it was completed and only 1 (possibly 2) will complete the study.
UK is the Reference Member State for Strattera in Europe. The information above warrants a new urgent safety review. I request that the MHRA initiates such a review and investigates this matter fully.
It is a well known fact that disastrous effects of a drug are not showing up in the short-term clinical trials being a requirement for licensing of a drug. Now a long-term clinical trial has been done – or more correctly “tried”. The results of 40 percent of the participants having to end the study in advance due to harmful effects, means that children and adults being subjected to long-term treatment with Strattera – in less well supervised conditions – are in a serious risk situation.
The MHRA should in keeping with its aim to protect public health take immediate actions to investigate this matter. I count on the agency to do so and look forward to an answer saying this the new safety review is started.
Jan Larsson
Writer
Sweden
[1] Gillberg/Kadesjö/Lilly, Ansökan till forskningsetikkommittén vid Göteborgs universitet, 29 november 2002, inkom 14 januari 2003. (Application to the Research Ethics Committee.) http://www.jannel.se/refs_strattera_trial/application_gillberg_strattera_ethics_committee.PDF
[2] Gillberg/Råstam/Cederlund, Angående klinisk läkemedelsprövning (atomoxetine hydrochloride) ref nr: 2002/74152; 25 april 2006. (Communication to the Swedish MPA.)
[3] Gillberg/Råstam/Cederlund, Angående klinisk läkemedelsprövning, 11 oktober 2005, inkom Läkemedelsverket den 13 oktober 2005. (Communication to the Swedish MPA.)
[4] Läkemedelsverket, e-postsvar av den 12 december 2005. (Data from the Swedish MPA.)"
BEFORE THAT WENT OUT there were other things going on, this is probably the one article that will give the general idea best of what is happening, by the same journalist:
"MHRA forbids Sweden to reveal Strattera suicide data
The British Medicines and Healthcare products Regulatory Agency (MHRA) has forbidden Swedish authorities to reveal Strattera suicide data. A release in Sweden of data about suicides and suicide attempts from Eli Lilly's Strattera is said to hurt the relations between the two countries.
/24-7PressRelease/ - SWEDEN - March 10, 2006 - Data about the harmful effects from the ADHD drug Strattera were revealed in a document from 9 December 2005, written by the British MHRA and sent to the Swedish MPA (Medical Products Agency). The information was gotten as a result of FOIA-requests, and released by court order.
The document told about 130 reports of suicidality in one month from treatment with Strattera. It told about 766 spontaneous reports of cardiac disorders and 172 of liver injury, and about 20 completed suicides. The 130 cases of suicidal and self-injurious behaviour were reported September 23 - October 25, 2005.
The main part of the information was classified and not released. So was, for example, the full assessment of all data about suicidality withheld from the public. That review - on which MHRA based their conclusions - was made by the manufacturer, Eli Lilly, and was named Annex 4 to the report. It would of course be of tremendous value for independent researchers to read how Lilly has treated the statistical data, but this has not been possible.
And now MHRA has forbidden Sweden to release Lilly's review. In a decision made by the Swedish MPA, as a result of a new FOIA-request, it is written that contact has been taken with the British authority MHRA and that the release of Lilly's suicide review would hurt the relations between the two countries! Thus the review cannot be released.
The MHRA, as well as FDA and other national medical agencies are supposed to be "watchdogs", supposed to protect the public from harmful effects of dangerous drugs. That the MHRA now gives directive to other countries to hide the information about Strattera suicide data is a big medical scandal.
All information about the harmful effects of this psychiatric drug should now be made public by the medical authorities and an impartial evaluation of the data should be done. Psychiatrist should no longer be allowed to prescribe poisonous drugs to normal children; children who do not have any objective abnormality but whose behaviour are deemed inappropriate."
You can see very recent email correspondence between the reporter and the MHRA and NICE.org here:
http://www.network54.com/Forum/281849/message/1147469794
Last edited by peagee (2006-05-23 04:29:30)
Offline
UPDATE ON STRATTERA:
SWEDISH COURT RELEASES DATA UNDER FREEDOM OF INFORMATION ACT - 10,988 ADVERSE PSYCHIATRIC REACTIONS REPORTED IN LESS THAN THREE YEARS
http://www.24-7pressrelease.com/view_press_release.php?rID=16662
"Strattera - 10,988 adverse "psychiatric reactions" reported in less than three years
In less than three years 10,988 adverse "psychiatric reactions" have been reported to Eli Lilly for the ADHD drug Strattera. This is revealed in a document treated as a "state secret" by the British and Swedish medical agencies.
/24-7PressRelease/ - HAGERSTEN, SWEDEN, August 01, 2006 - The document, Psychiatric Adverse Events including Cumulative review of spontaneous reports of suicidal and self-injurious behaviour, is an attachment to an unpublished report about Strattera from the British Medicines and Healthcare products Regulatory Agency (MHRA), January 2006.
The attachment, mentioning the 10,988 "psychiatric reactions", also gives a good insight into how psychiatric drugs and drug cocktails are killing children and adults, and how psychiatric diagnoses are used to hide the harmful effects of drugs.
A court in Sweden has recently ordered the document to be made public.
This was done after the Swedish Medical Products Agency (MPA) and the British MHRA in their response to FOIA [FREEDOM OF INFORMATION ACT] requests had treated this document as if it was a "state secret".
In its arguments to the court the Swedish MPA even said that issuance of it would hurt the relations between Sweden and UK. Neither the British National Institute for Health and Clinical Excellence (NICE), responsible for "guidance on the appropriate treatment", being in possession of the document, was willing to reveal the data in it. NICE said in an answer to a FOIA-request that the document was "received in confidence and disclosure of that information would amount to an actionable breach of confidence".
These agencies, responsible for protecting the public from harmful drugs and for "appropriate treatment", consider a document reviewing the "suicidal and self-injurious behaviour" caused by a psychiatric drug in the category of state secrets, and that it would be "an actionable breach of confidence" to let the public know about these data.
But a court in Sweden has made the document public. The document consists mainly of Eli Lilly's review of the 431 cases of suicidal and self-injurious behaviour reported for Strattera from November 2002 up to October 2005. 130 of these reports were submitted in one month (October 2005), after the warnings were issued in September that Strattera increased the risk for suicidality.
Lilly's review is an excellent example of how to explain away suicides, suicide attempts and suicide ideation caused by psychiatric drugs - and of how the assessing medical agency then buys these explanations.
It can be seen in the review that children and adolescents in many cases are getting psychiatric drug cocktails - Strattera together with antidepressant SSRI drugs (as Zoloft and Prozac) and antipsychotic drugs (as Risperidone and Zyprexa). The reason for the adding of more drugs to the first one, is that one psychiatric drug's harmful effect - according to the psychiatric ideology - is seen as yet another "psychiatric disorder", to be treated with yet another mind altering (poisonous) drug. And so on.
The alleged psychiatric brain disorder ADHD (without any objective abnormality) is NOT associated with suicidal thoughts in its list of "symptoms". However as the reports of suicidal behaviour from "treatment" with Strattera kept coming in, Eli Lilly had to connect depression and suicidal behaviour with ADHD, to exonerate the drug and blame it on the children's "underlying condition". For this purpose Eli Lilly claimed in its submission to the FDA in September 2005: "Depression is present in up to 40% ...of ADHD adolescents and children."
It is very convenient for drug companies that psychiatrists are adding more poisonous drugs to the first one when its harmful effects are showing up. No single drug can then be blamed for the death of children.
It is even more convenient to blame the harmful effects of a drug on a (presumed) "underlying condition". This is what Eli Lilly and the psychiatric experts at the MHRA are doing when they in cases of suicidal behaviour in connection with Strattera find "confounding factors" present. No matter how obvious the case of poisoning the conclusions from the medical agency become (at best): "the possibility that atomoxetine [Strattera] may have exacerbated the individuals underlying condition in these cases cannot be excluded."
In its report about Strattera (January 2006) the MHRA talks about "the large number of psychiatric reactions". It says the agency in September 2005, due to this large number of harmful effects, had requested Eli Lilly "to perform a cumulative review of all psychiatric disorders reported for atomoxetine [Strattera]".
In the attachment, containing the review by Eli Lilly of suicidal behaviour, no review of "the large number of psychiatric reactions" can be found. What can be found is the number of reported reactions (up to September 2005): 10,988 adverse "psychiatric reactions" described in 6,751 reports. Example of reactions: The two categories aggression and anger are reported in 1117 cases, abnormal behaviour in 989 cases, and homicidal ideation in 19 cases.
The MHRA has still not let the public know any details about this "large number of psychiatric reactions". Neither has the agency let the public know the updated figures for suicidal behaviour in connection with Strattera..."
Offline
AND NOW ELI LILLY'S DRUG PUSHERS ARE OUT, WORKING TO UNDO THE DAMAGE AND ENSURE MORE KIDS GET GIVEN A FAILED SNRI WITH A TON OF ADVERSE SIDE EFFECTS:
http://today.reuters.co.uk/news/newsArticle.aspx?type=healthNews&storyID=2006-08-03T182211Z_01_HAR366091_RTRIDST_0_HEALTH-STRATTERA-YEARS-DC.XML&archived=False
Strattera seen effective for ADHD over 2 years
Thu Aug 3, 2006 7:22 PM BST
By Megan Rauscher
NEW YORK (Reuters Health) - Pooled data from 13 trials indicate that the drug Strattera, known technically as atomoxetine, continues to work well for teens with attention deficit/hyperactivity disorder (ADHD) over at least two years, with no surprise side effects.
In comments to Reuters Health, Dr. Timothy E. Wilens from Massachusetts General Hospital, Boston, said: "Given that atomoxetine is relatively new to the market, our longer term findings in adolescents are reassuring in that the medication continues to be effective without evidence of tolerance and is well tolerated without any unforeseen side effects emerging with chronic use."
Wilens and colleagues note in the Journal of Pediatrics that young children with ADHD are often treated with the stimulant drug Ritalin, but Strattera, a nonstimulant, has appeal for use in older children and adolescents with ADHD; it is dosed once daily, limited abuse potential, and has a long duration of action.
The researchers report on 601 subjects 12 to 18 years of age treated with Strattera in clinical trials. Of these, 219 completed at least 2 years of treatment.
According to the authors, Strattera produced "significant improvement" in ADHD symptoms over the first 3 months of treatment, and symptoms remained improved up to 2 years without the need to up the dose of the drug.
During the 2-year period, 99 subjects (16.5 percent) stopped taking Strattera due to lack of effectiveness and 31 (5.2 percent) discontinued treatment due to side effects.
Mirroring past studies, the most frequently cited reasons for discontinuation were nausea, stomach ache, and headache. There was no evidence of height or weight growth deficits in adolescents treated for up to 2 years with Strattera.
Recently, two cases of liver injury related to Strattera were reported among the roughly 2.4 million patients who have used the drug to date, the team notes. In the current study, there were no "clinically significant" liver function test abnormalities.
"Despite the increasing recognition of the persistence of ADHD into adolescence, there remains a paucity of treatment data in this age group," Wilens and colleagues write. The results of this investigation support the longer-term use of Strattera in adolescents with ADHD, they conclude.
The study was supported by ELI LILLY AND COMPANY of Indianapolis, Indiana, MAKER OF STRATTERA.
SOURCE: Journal of Pediatrics, July 2006."
(ie, the manufacturer funds the study and the psychiatrists 'find' results that Eli Lilly want - regardless of what harm it does to our children)
Offline
FURTHER, its NOT a NEW drug, its a FAILED SNRI - similar to an SSRI - IT FAILED.
And in the world of pharmaceutical marketing for 'antidepressants' its fairly HARD to FAIL an Antidepressant. So - how bad was Strattera as an antidepressant?
Can't change words to bold here to highlight so have done a few in UPPER CASE so they stand out.
http://ahrp.org/infomail/04/04/26.php
Recycled drugs: FAILED antidepressants-- Stratera marketed for ADHD; Cymbalta for incontinence
Mon, 26 Apr 2004
A front page article in The Wall Street Journal (excerpt below) provides a roadmap of FAILED Eli Lilly drugs which the company repackaged for a different condition than the one for which the drugs had been tested in clinical trials, or to expand the market for drugs that don't bring in enough profits when marketed for a particular condition.
The Journal notes: "Lilly has long had a culture that looks at failure as an inevitable part of discovery and encourages scientists to take risks. If a new drug doesn't work out for its intended use, Lilly scientists are taught to look for new uses for a drug."
The Journal lists 8 failed Lilly drugs that were recycled or in the process of being recycled. Among the drugs that bombed are TWO ANTIDEPRESSANTS that have been REPACKAGED.
Strattera and Cymbalta are antidepressants of the selective norepinephrine reuptake inhibitor (SNRI) class. In clinical trials Strattera had FAILED as an antidepressant, but is now a hot-selling drug euphemistically marketed as a "non-stimulant" treatment for ADHD..."
Offline
Isn't it amazing that with all those side effects, the site STRATTERA.COM - can only work themselves up to saying this on their site?
http://www.strattera.com/1_2_taking_strattera/1_2_2_effects_children.jsp
Side Effects — Children and Adolescents
Most children in clinical trials who experienced side effects were not bothered enough to stop taking Strattera. The most common side effects were upset stomach, decreased appetite, nausea or vomiting, dizziness, tiredness, and mood swings.
As with all ADHD medications, growth should be monitored during treatment although height and weight data measured for up to 3 years indicates minimal, if any, long-term effects.
In rare cases, Strattera can cause allergic reactions, such as swelling or hives, which can be serious. Your child should stop taking Strattera. Call your doctor or healthcare professional if your child develops any of these symptoms. Strattera has not been tested in children under 6 years of age.
This is not a complete list of possible side effects. Contact your doctor or healthcare professional if your child develops any unusual symptoms. "
No mention of suicidality, just a 'contact your doctor'. And where do THEY get their information from?
Places like Eli Lilly's STRATTERA.COM much of the time.
IN addition to the nearly 11,000 psychiatric adverse events as mentioned in the previous 'swedish court releases document' article, there's also the little matter of cardiac disorders, liver injury and completed suicides:
http://www.24-7pressrelease.com/view_press_release.php?rID=11901
"...It told about 766 spontaneous reports of cardiac disorders and 172 of liver injury, and about 20 completed suicides. The 130 cases of suicidal and self-injurious behaviour were reported September 23 - October 25, 2005..."
For anyone in the UK, isn't it a little odd that the MHRA (and the closely intertwined NICE.org) whose job it is to look after public interests would fight even the Freedom of Information Act to keep these things away from public knowledge?
The same applies to Sweden.
Are they protecting you? Why not? They keep hidden side effects that could cause a child's suffering or even suicide, instead of disclosing them so that parent and physicians are warned and at least able to keep a watch out for any signs of a problem (if prescribed at all).
I don't know about Swedish regulators, but one good reason the UK's MHRA may be more interested in protecting Eli Lilly (et al) than the public is that the MHRA is 100% paid for by the pharmaceutical industry they purport to protect the public from - even though people assume that as a 'government health' department they'd be paid independently of the industry they are purportedly 'guarding' us from.
Odd, huh? So ... what other drugs and serious side effects are they pretending to 'protect' us against? How many people have suffered or died because the MHRA have approved drugs for use and omitted to mention the risks?
Maybe you don't believe the MHRA are funded by the Pharmaceutical Industry? Then see the article re this at:
http://www.guardian.co.uk/uk_news/story/0,3604,1318946,00.html
"...Since 1989, when the then prime minister, Margaret Thatcher, took drug regulation out of the hands of the Department of Health, the MHRA has been 100% funded by the pharmaceutical companies...."
Last edited by peagee (2006-08-05 08:54:53)
Offline
I can recommend a reputable pharmacy (Strattera) - www.24tabs.org I received the order and it was on time and the pills work great.
Offline
© 2002-2010 YourLawyer.com. All Rights Reserved.
Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.